DE60305052T2 - Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden - Google Patents

Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden Download PDF

Info

Publication number
DE60305052T2
DE60305052T2 DE60305052T DE60305052T DE60305052T2 DE 60305052 T2 DE60305052 T2 DE 60305052T2 DE 60305052 T DE60305052 T DE 60305052T DE 60305052 T DE60305052 T DE 60305052T DE 60305052 T2 DE60305052 T2 DE 60305052T2
Authority
DE
Germany
Prior art keywords
alkyl
cycloalkyl
phenyl
independently
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305052T
Other languages
German (de)
English (en)
Other versions
DE60305052D1 (de
Inventor
Hui San Diego CAI
I. Nicholas Poway CARRUTHERS
A. Curt San Diego DVORAK
P. James San Diego EDWARDS
K. Annette Concord KWOK
Jianmei San Diego WEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60305052D1 publication Critical patent/DE60305052D1/de
Publication of DE60305052T2 publication Critical patent/DE60305052T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60305052T 2002-09-06 2003-09-05 Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden Expired - Lifetime DE60305052T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40872302P 2002-09-06 2002-09-06
US408723P 2002-09-06
PCT/US2003/028017 WO2004022537A2 (en) 2002-09-06 2003-09-05 Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands

Publications (2)

Publication Number Publication Date
DE60305052D1 DE60305052D1 (de) 2006-06-08
DE60305052T2 true DE60305052T2 (de) 2006-12-21

Family

ID=31978666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305052T Expired - Lifetime DE60305052T2 (de) 2002-09-06 2003-09-05 Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden

Country Status (12)

Country Link
US (3) US7226938B2 (https=)
EP (1) EP1543011B1 (https=)
JP (1) JP4596915B2 (https=)
AT (1) ATE325125T1 (https=)
AU (1) AU2003272285A1 (https=)
CA (1) CA2497868C (https=)
CY (1) CY1105080T1 (https=)
DE (1) DE60305052T2 (https=)
DK (1) DK1543011T3 (https=)
ES (1) ES2264534T3 (https=)
PT (1) PT1543011E (https=)
WO (1) WO2004022537A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1543011B1 (en) * 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US20080102476A1 (en) * 2003-09-26 2008-05-01 Lars Karlsson Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood
JP2007517056A (ja) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
MXPA06014535A (es) 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de la inflamacion.
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
EP1776982A1 (en) * 2005-10-18 2007-04-25 Argenta Discovery Limited Pyrimidine compounds as histamine modulators
WO2006056848A1 (en) * 2004-11-24 2006-06-01 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
EP1671972A1 (en) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
BRPI0519774A2 (pt) 2005-01-19 2009-02-10 Biolipox Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
EP2455075B1 (en) 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
EP1767537A1 (en) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
NZ569608A (en) 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2007117399A2 (en) 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
CN101421228B (zh) 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
CA2659060A1 (en) * 2006-06-30 2008-01-10 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
BRPI0915526A2 (pt) * 2008-06-12 2016-01-26 Janssen Pharmaceutica Nv uso de um antagonista da histamina h4 para o tratamento de aderências pós-operatórias
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US20120277238A1 (en) * 2009-07-31 2012-11-01 Shionogi & Co., Ltd Pharmaceutical composition containing fused hetero-ring derivative
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
PT2964229T (pt) 2013-03-06 2020-03-23 Janssen Pharmaceutica Nv Moduladores de piridina benzimidazol-2-ilo do recetor h4 de histamina
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
CN109499595B (zh) * 2018-11-16 2021-10-08 中国林业科学研究院林产化学工业研究所 一种氧还原反应（orr）催化剂gpncs及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571723B1 (fr) * 1984-10-12 1988-08-26 Lipha Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant
NZ223654A (en) * 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
DE60007592T2 (de) 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
EP1543011B1 (en) * 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands

Also Published As

Publication number Publication date
DK1543011T3 (da) 2006-08-07
EP1543011B1 (en) 2006-05-03
CY1105080T1 (el) 2009-11-04
US7645758B2 (en) 2010-01-12
US20070185120A1 (en) 2007-08-09
US20070185131A1 (en) 2007-08-09
JP2006500394A (ja) 2006-01-05
CA2497868A1 (en) 2004-03-18
AU2003272285A1 (en) 2004-03-29
US20040048878A1 (en) 2004-03-11
WO2004022537A2 (en) 2004-03-18
CA2497868C (en) 2010-11-30
PT1543011E (pt) 2006-08-31
ES2264534T3 (es) 2007-01-01
US7226938B2 (en) 2007-06-05
DE60305052D1 (de) 2006-06-08
AU2003272285A8 (en) 2004-03-29
WO2004022537A3 (en) 2004-05-06
ATE325125T1 (de) 2006-06-15
JP4596915B2 (ja) 2010-12-15
EP1543011A2 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
DE60305052T2 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
DE69603240T2 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DE69613240T2 (de) N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden
DE69834842T2 (de) Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
DE60203263T2 (de) Pyrazolderivate gegen tgf überexprimierung
DE69112895T2 (de) Pharmazeutische Verbindungen.
DE69229114T2 (de) 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
DE69118388T2 (de) Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
DE3782687T2 (de) Aminoimidazochinolin-derivate.
EP0049355A1 (de) 7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-(naphthyridin oder chinolin)-3-carbonsäuren, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69015541T2 (de) Chinolinderivate, deren Herstellung und Verwendung.
CH654306A5 (de) Substituierte 1h-pyrazolo-(1,5-a)-pyrimidine.
DE69110685T2 (de) Substituierte imidazobenzazepine und imidazopyridoazepine.
DE60214401T2 (de) Hetero-bicyclische crf-antagonisten
DE60213851T2 (de) Ringannelierte pyrazolderivate
DE60216128T2 (de) Thieno[2,3-D]Pyrimidine mit kombinierter LH und FSH agonistischen Wirkung
DE60123643T2 (de) Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
DE3881407T2 (de) Cinnolin-Karbonsäure-Amide und Verfahren zu deren Herstellung.
DE69622677T2 (de) Hemmer der Prolaktinsynthese
DE1934172A1 (de) Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
DE69004389T2 (de) Heteroarylsubstituierte Imidazo[4,5-c]pyridine.
EP1833830A1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
DE10053813A1 (de) Neue Verwendung von Sulfonamiden
DE60302344T2 (de) 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
DE60304048T2 (de) 2-thia-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition